Company: NCEL
Filing Date: 2025-06-30
Form Type: 6-K
Source: 0001213900-25-059248
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-06-30
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private
Issuer

Pursuant to Rule 13a-16
or 15d-16

under the Securities Exchange
Act of 1934

For the month of June 2025
(Report No. 4)

Commission file number:
001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s
name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive
offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form
40-F ☐

CONTENTS</div>

On June 26, 2025, NLS Pharmaceutics
Ltd, or the Company, executed an amendment, or the Amendment, to the Securities Purchase Agreement initially executed by and among the
purchasers thereto on March 27, 2025, or the Securities Purchase Agreement, relating to a private placement offering. Pursuant to the
initial closing contemplated by the Securities Purchase Agreement, the Company issued 1,212,122 preferred shares, par value CHF 0.03
per share, or the Preferred Shares, at a conversion price of $1.65 per share, as well as warrants to purchase 787,880 common shares at
an exercise price of $1.80 per share, for aggregate gross proceeds of $2 million.

Pursuant to the terms of the Securities
Purchase Agreement, the investors had the option to purchase an additional $1 million of Preferred Shares at a purchase price of $1.65
per share, in a subsequent transaction on identical terms as the initial closing. Pursuant to the terms of the Amendment, the investors
agreed to purchase preferred participation certificates, or PPCs, in lieu of preferred shares, with the same rights and privileges as
the Preferred Shares. Pursuant to the terms of the Securities Purchase Agreement and the Amendment, the Company agreed to issue 606,061
PPCs, as well as warrants to purchase 393,939 common shares at an exercise price of $1.80 per share, for aggregate gross proceeds of $1
million. The second closing occurred on June 27, 2025.